We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Deep Learning Powered AI Algorithms Improve Skin Cancer Diagnostic Accuracy

By LabMedica International staff writers
Posted on 16 Apr 2024
Print article
Image: AI can improve the accuracy of skin cancer diagnoses (Photo courtesy of 123RF)
Image: AI can improve the accuracy of skin cancer diagnoses (Photo courtesy of 123RF)

Artificial intelligence (AI) algorithms are increasingly being utilized in various clinical settings, such as dermatology. These algorithms are developed by training a computer with hundreds of thousands or millions of images of various skin conditions, each labeled with details like the diagnosis and patient outcomes. Through a process known as deep learning, the computer learns to identify patterns in the images that are indicative of specific skin diseases, including cancers. Once sufficiently trained, the algorithm can suggest potential diagnoses based on new images of a patient’s skin. However, these algorithms do not operate in isolation; they are used under the supervision of clinicians who evaluate the patient, make their own diagnostic assessments, and decide whether to follow the algorithm's recommendations.

Now, a new study led by researchers at Stanford Medicine (Stanford, CA, USA) has found that AI algorithms, which utilize deep learning, can enhance the accuracy of diagnosing skin cancers. This benefit extends to dermatologists, though the improvement is more pronounced for non-dermatologists. The study analyzed 12 research papers that documented over 67,000 evaluations of possible skin cancers by various medical practitioners, both with and without AI assistance. Findings indicated that healthcare practitioners without AI support accurately diagnosed approximately 75% of actual skin cancer cases and correctly identified about 81.5% of non-cancerous conditions that resembled cancer. The performance of healthcare practitioners improved when they used AI to assist with diagnoses. Their sensitivity increased to about 81.1% and their specificity to 86.1%.

Although these improvements might appear modest, they are crucial for correctly diagnosing patients who are either mistakenly told they do not have cancer when they do, or incorrectly informed they have cancer when they do not. The analysis further revealed that medical students, nurse practitioners, and primary care physicians gained the most from AI assistance, with average improvements of approximately 13 points in sensitivity and 11 points in specificity. While dermatologists and dermatology residents already showed higher overall accuracy, their diagnostic performance also saw gains in sensitivity and specificity with AI assistance. The researchers are now looking to further explore the potential and challenges of integrating AI tools into healthcare, particularly focusing on how physicians' and patients' perceptions and attitudes towards AI could affect its adoption.

“Previous studies have focused on how AI performs when compared with physicians,” said postdoctoral scholar Jiyeong Kim, PhD. “Our study compared physicians working without AI assistance with physicians using AI when diagnosing skin cancers.”

Related Links:
Stanford Medicine

Gold Member
Troponin T QC
Troponin T Quality Control
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Ultra-Low Temperature Freezer
iUF118-GX
New
Pipet Controller
Stripettor Pro

Print article

Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.